Affiliations
Yi Bao, Gabriel Cruz, Yuping Zhang, Yuanyuan Qiao, Rahul Mannan, Jing Hu, Fan Yang, Mahnoor Gondal, Miriam Shahine, Sarah Kang, Somnath Mahapatra, Alec Chu, Jae Eun Choi, Jiali Yu, Heng Lin, Stephanie J Miner, Dan R Robinson, Yi-Mi Wu, Yang Zheng, Xuhong Cao, Fengyun Su, Rui Wang, Noshad Hosseini, Marcin Cieslik, Ilona Kryczek, Ulka Vaishampayan, Weiping Zou, Arul M Chinnaiyan
DOI: 10.1158/2159-8290.CD-24-0435
Abstract
Our study reveals UBA1 as a predictive biomarker for clinical outcomes in ICB cohorts, mediating cancer immune evasion and ICB resistance. We further highlight JAK1 stabilization as a key mechanism of UBA1 inhibition and nominate the UBA1-STUB1 axis as an immuno-oncology therapeutic target to improve the efficacy of ICB.
Keywords
UBA1-STUB1，CD90，ICB，JAK1
関連製品
| カタログ番号 | 製品名 | 説明 | ターゲット |
|---|---|---|---|
| MY557227 | CD90 | Thy-1 membrane glycoprotein, Thy-1 antigen, CD90, Thy1, Thy-1 |
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
中文
English
한국어
日本語
Español
Français
Русский